DESIGN AND DEVELOPMENT OF LOSARTAN POTASSIUM FLOATING DRUG DELIVERY SYSTEMS by Mohapatra, Prasanta Kumar et al.
 
 




PRASANTA KUMAR MOHAPATRAa*, CH. PRATHIBHAb, VIVEK TOMERa, MANDEEP KUMAR GUPTAa, SATYAJIT 
SAHOOc 
aMoradabad Educational Trust Group of Institutions Faculty of Pharmacy, Moradabad, Utter Pradesh, India, bLydia College of Pharmacy, 
East Godavari District, Andhra Pradesh, India, cC. U. Shah College of Pharmacy and Research, Surendranagar, Gujrat, India 
Email: 
Received: 27 Jul 2018, Revised and Accepted: 12 Sep 2018 
mahapatra.kjr@gmail.com 
ABSTRACT 
Objective: The current study was projected to prepare a losartan potassium gastroretentive drug delivery system (GRDDS) of floating tablets was 
planned to enhance the gastric residence time, thus prolong the drug release. 
Methods: Effervescent floating matrix tablets of losartan potassium were prepared by direct compression technique using polymers like HPMC 
k4m, guar gum, and gum karaya, with lubricants magnesium stearate and talc. In the present study, sodium bicarbonate was incorporated as a gas 
generating agent. Total nine formulations were designed and evaluated for pre-compression parameters known as the angle of repose, bulk density, 
tapped density, Hausner’s ratio, compressibility index, and post-compression parameters are uniformity of weight, hardness, and drug content 
percentage, variability, in vitro buoyancy, dissolution studies, and Fourier transform infrared spectroscopy (FTIR).  
Results: An in vitro dissolution study was carried out by using buffer pH 1.2. From in vitro dissolution studies, it has been found that an increase in 
polymer concentration diminishes the drug release profile. The in vitro drug release percentage from F4-F9 formulations ranged from 60.28%-
98.66% at the closing of 12 h and buoyancy found over 12 h.  
Conclusion: The in vitro drug release from F1-F3 and F7-F9 followed zero-order, F4 followed Higuchi order, F5 and F6 followed Hixon-Crowell 
release kinetics. The drug release mechanism was set up to be F1-F8 non-Fickian (anomalous behavior) and F9 having Fickian diffusion type. 
Keywords: Losartan potassium, Hpmc k4m, Guar gum, and Gum karaya, Direct compression technique, Floating drug delivery systems (FDDS) 




The oral route is the most convenient and extensively used route for 
drug administration in the body. It is likely that at least 90% of all 
the drugs administered by the oral route [1]. The oral route is the 
most preferred route, and it received more interest in the pharmacy 
sector because it provides more flexibility in designing of the dosage 
form as compared to another path. There are different drug 
deliveries to administer the drug by the oral route. The two 
difficulties of drug delivery systems (DDS) are, less gastric retention 
time and less gastric emptying (GE) time. Decrease response of dose 
due to, incomplete drug release from the dosage form in the 
absorption zone [2, 3]. Due to physiological property the drug, 
absorption is unsatisfactory and highly fluctuating among and 
between individuals and generally affected by the gastrointestinal 
transit of the form, specifically its residence time in gastric, which 
seems to be one of the important causes of the overall transit time 
variability [4]. In the delivery of drugs with narrow absorption 
windows in the small intestinal region, the gastric retention will 
provide advantages [4]. Various approaches have been hypothesized 
to control the residence of DDS in the upper part of the 
gastrointestinal tract (GIT) such as the incorporation of passage 
delaying food agents, ion exchange resins, raft system, high-density 
DDS, floating drug delivery systems (FDDS), swelling or expandable 
DDS and mucoadhesive DDS [5, 6, 22]. The oral controlled DDS main 
objective is to attain more expected and enhanced bioavailability [7]. 
The common property of conventional controlled release (CR) 
technologies is that a large part of the drug load is released in the 
colon, where the dosage form stays for a relatively long period. This 
delivery approach, while desirable for many molecules, was found to 
be inappropriate for drugs that are poorly absorbed from the lower 
portion of the GIT. Under certain circumstances extending the 
gastric retention of a DDS is necessary for achieving the bigger 
therapeutic advantage of the drug. The benefit of gastric retention is 
for those drugs that are absorbed in the proximal portion of the GIT, 
and the drugs that are having a solubility less or a dip in the alkaline 
pH may advantage of gastric retention [8]. Drug delivery to the 
proximal small intestine and local and sustained drug delivery to the 
abdominal to treat certain diseases, extending gastric retention of the 
therapeutic substance may offer several benefits including 
enhancement of therapeutic efficacy and possible reduction of the 
dose size, improved bioavailability [9]. Fundus and body is a 
component part of the proximal stomach, which functions as a 
reservoir for swallowing materials, whereas the major site of mixing 
motions is the distal region (pylorus), conveying as a pump to push 
gastric contents for GE [10, 22]. In, fasting as well as fed states the GE 
occurs. As a consequence of gastric contractions, the GE occurs and 
nature depends upon the contents of the stomach. The appropriate 
classification of GE can be digestible solids, indigestible solids and GE 
of liquid. Due to the generation of intragastric pressure because of the 
gentle muscular contractions happening mainly from the proximal 
stomach, i.e. from the upper body of the stomach the liquids can be 
removed [11]. Compare to all the DDS the FDDS have a bulk density is 
lesser than gastric fluids and so linger buoyant in the stomach without 
disturbing GE rate for an extended period of time [22]. 
MATERIALS AND METHODS 
Materials 
Losartan potassium was procured from Farma glow Ltd, Mumbai, 
India and guar gum were procured from Oxford Chemicals, Delhi. 
Gum karaya and HPMC k15m are obtained from NR chemicals 
limited, Mumbai. Talc and magnesium stearate were procured from 
SD Fine Chem. Ltd, Mumbai, India, and sodium bicarbonate were 
obtained from Rankem Ltd., Delhi. The residual reagents which were 
used having an analytical grade [16, 17]. 
Methods 
Preparation of losartan potassium floating tablets 
All the required ingredients sufficient for 20 tablets were weighed 
accurately and thoroughly mixed after passing through the sieve no. 
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22 in order to attain uniformity. Initially, required an amount of the 
active ingredient, i.e., losartan potassium and the polymer (guar 
gum/gum karaya/HPMC k4m/a combination of these polymers) 
were calculated accurately and were mixed thoroughly with each 
other. Later on, an accurate amount of the effervescent agent 
NaHCO3 was added to the powder and mixed individually. Then the 
diluent, i.e., mannitol was mixed uniformly with the blend. 
Magnesium stearate and talc were then mixed with the tablet 
mixture as a lubricant. Tablets containing losartan potassium 
equivalent to 138.5 mg were compressed by using the 10.0-
millimeter diameter, spherical tablet punches on a 16 station rotary 
compression machine at the hardness of 5 to 6 kg/cm2
Evaluation parameters 
. The 
composition of all formulations was given in table 1 [14, 19]. 
Pre-compression parameters of losartan potassium granules 
Angle of repose  
The angle of repose has been set at the maximum angle possible 
between the surfaces of a pile of powder and horizontal plane. Here 
the fixed funnel method was employed. A funnel was set with its 
crest at a given height (h), above a level horizontal surface on which 
a graph paper was placed. The powder was watchfully poured 
through a funnel till the apex of the conical pile just touches the top 
of the funnel. By using the below-given formula, the angle of repose 
was calculated [14, 18]. 
 
Where,  
θ = angle of repose, 
h = height of pile,  
r = radius of the pile. 
Bulk density  
It is the ratio of the mass of the powder taken with its bulk volume. 
The shape and cohesiveness of particles, particle size distribution, was 
depended on bulk density. A fixed quantity of powder was cautiously 
poured into the graduated measuring cylinder through an appropriate 
size funnel and volume was calculated, and it is called as bulk volume. 
Bulk density is expressed in kg/m3and is given by [15, 18]. 
 
Where,  
ρb = bulk density (kg/m3
M = mass of powder (kg), 
), 
Vo = bulk volume of powder (m3
Tapped density  
). 
In a clean, dry 100 ml measuring cylinder 10 g of powder was 
loaded. The loaded cylinder was then tapped 100 times by tapped 
density apparatus or manually by hand from a fixed height and then 
tapped volume, tapped density was measured. 
Which is specified in kg/m3and calculated by following formula [14, 18]. 
 
Where,  
ρ t= tapped density (kg/m3
M = mass of powder (kg), 
), 
Vt = tapped volume of powder (m3
Compressibility index 
). 
From the values of bulk and tapped densities a secondary method 
for determining powder flow is Carr’s index. The powder arch 
potency or bridge strength and stability of the powder were directly 
measured by the percentage compressibility. Each formulation’s 
Carr’s index was calculated by the below-given equation [15, 18]. 
Carr’s index =  
Where, 
ρ t  = tapped density (kg/m3
ρ
), 
b = bulk density (kg/m3
Hausner’s ratio 
) 
Hausner’s ratio is calculated by tapped density versus bulk density [18]. 
 
Post-compression parameters 
Tablet thickness and diameter 
Thickness, as well as the diameter of the tablets, was determined by 
using a vernier caliper. By picking three tablets from each 
formulation individually and randomly the tablet's thickness was 
measured [14, 16, 17]. 
Hardness 
The hardness test is used to check the binding strength of a tablet. 
Due to tablets, insufficient hardness may undergo chipping or 
breakage during transportation or breakage during handling. 
Randomly five tablets were selected and with the help of Monsanto 
hardness tester hardness of each tablet was calculated. The tablet 
hardness is commonly measured in kg/cm2 
Friability 
[16, 21]. 
By taking randomly 20 tablets into Roche friabilator, the friability of 
tablets was determined. It is expressed in percentage. Primarily 20 
tablets were weighed and transferred into Roche friabilator. At, 25 rpm 
for 4 min the friabilator drum was rotated, or the drum was rotated total 
100 revolutions. After completion of 100 revolutions, the 20 tablets were 
removed and again weighted. The weight loss percentage was then 
measured by the below-given equation [15, 16, 17]. 
 
Where, 
f = friability,  
W0 
W = final weight. 
= initial weight,  
Uniformity of weight 
The weight variation arises due to the non-uniform size of granules, 
poor flow property, and mechanical problems. If the granular size is 
large, non-uniformly the dies will be filled. And due to the formation 
of non-uniform size tablets, the drug content also became non-
uniform. 
Method: Uncoated tablets comply with this test. 
The 20 tablets average weight is determined and compared with 
individual weight. From the average weight, not more than two 
tablets deviate from a percentage larger than that given. If more 
than two tablet weight is outside the±average percentage weight 
then (according to IP) the test will be failed [14, 15, 17]. 
Uniformity of drug content 
In the formulation, the drug content was checked the dose 
uniformity. Randomly 10 tablets were selected individually and 
powered. The randomly selected powdered individual tablets were 
placed in a 100 ml volumetric flask containing pH 1.2 buffer solution 
and left undisturbed overnight. The drug content was determined 
after suitable dilutions by U. V-spectrophotometer at 234 nm against 
blank [14, 19, 21]. 
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Buoyancy studies 
To evaluate the floating lag time and extent of floating the in vitro 
buoyancy was conducted. The glass beaker containing 0.1 N HCl 250 
ml buffer pH 1.2 into it, the tablets were placed. Then the floating lag 
time (tablet to reach from the water inside to surface) and entire 
floating time (tablet’s floating duration) were measured [14, 19, 20]. 
Drug excipients compatibility studies 
In all pharmaceutical dosage forms, the excipients are found almost 
as integral components. The careful selection of the excipients is the 
successful formulation of a stable and effective solid dosage form. 
The role of excipients to simplify administration, promote the 
bioavailability and the constant release of the drug and also protect 
it from deterioration. One of the strongest analytical techniques to 
detect functional groups of a drug is infrared spectroscopy. Fourier 
transform infrared spectroscopy (FTIR) studies the interaction 
between a pure drug and its formulations were evaluated. In the 
current study, the employed method was a potassium bromide 
pellet method. The dry powdered potassium bromide was 
thoroughly mixed with the sample. The mixture was then compacted 
by using dies to form a disc. In the spectrophotometer, the spectrum 
was recorded after placing the disc [16, 17, 20]. 
In vitro dissolution studies using pH 1.2 buffer 
In, USP Type II apparatus (paddle type) the release rate of 
losartan potassium floating tablets was determined. By using 
900 ml of 0.1N HCl, (pH 1.2) at 37±0.5 ˚C at 50 rpm for 12 h the 
dissolution test was conducted. From the dissolution apparatus, 
the 5 ml sample was withdrawn at a specified time intervals, and 
every time 5 ml of fresh dissolution medium was replaced. 
Through a 0.45 µm membrane filter, the collected samples were 
filtered and if necessary diluted. These sample solutions’ 
absorbance was measured at 234 nm by using a U. V-Visible 
spectrophotometer [14, 19, 21]. 
Drug release kinetics 
To inspect the drug release mechanism and kinetics, the cumulative 
percentage of drug release data were fitted to models presenting zero-
order (cumulative percentage of drug release versus time), first-order 
(log cumulative percentage of drug remaining versus time), Higuchi 
(cumulative percentage drug release versus square root of time), Hixon-
Crowell (cube root of drug percentage remaining versus time in ‘h’) and 
Korsmeyer-Peppas (log cumulative percentage drug release versus log 
time) correspondingly [14, 17, 20]. 
RESULTS AND DISCUSSION 
Pre-compression parameters of losartan potassium granules 
The losartan potassium formulations F1 to F9 the Carr’s index and 
Hausner’s ratio data between 11.51 (F7) to 15.13 (F1) and 1.13 (F7) 
to 1.18 (F8). The losartan potassium prepared tablets bulk density 
and tapped density was found in between 0.326 (F6) to 0.392 (F7) 
and 0.377 (F4) to 0.443 (F7) respectively. The angle of repose values 
range is in between 20.14 (F1) to 29. 2 (F6) indicate good flow 
property about the granules. 
Post-compression parameters 
In the formulations, the drug content values vary from 98.25% (F2) 
to 99.49% (F5). The hardness and friability of the prepared gastro 
retentive drug delivery system (GRDDS) of losartan potassium were 
found in between the range of 5.02 (F1) to 5.94 (F2) kg/cm2
 
 and 
0.14% (F9) to 0.52% (F6). The thickness and weight variation data 
of the GRDDS of losartan potassium tablets were found in between 
3.93 mm (F4) to 4.24 mm (F5) and 296.45 mg (F5) to 301.12 mg 
(F4), were presented in table 3. 
Table 1: Formulation composition of losartan potassium 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Losartan potassium 138.5 (%w/w) 138.5 138.5 138.5 138.5 138.5 138.5 138.5 138.5 
HPMC K4M 69.25 (%w/w) - - 103.875 - - 34.625 34.625 - 
Guar gum - (%w/w) 69.25 - - 103.875 - - 34.625 34.625 
Gum karaya - (%w/w) - 69.25 - - 103.875 34.625 - 34.625 
Mannitol 30.25 (%w/w) 30.25 30.25 45.625 45.625 45.625 30.25 30.25 30.25 
Sodium bicarbonate 50 (%w/w) 50 50 50 50 50 50 50 50 
Talc 6 (%w/w) 6 6 6 6 6 6 6 6 
Magnesium Stearate 6 (%w/w) 6 6 6 6 6 6 6 6 
Total Weight (mg) 300 300 300 350 350 350 300 300 300 
HPMC-Hydroxy propyl methyl cellulose 
 
Table 2: Pre-compression parameters 




3 Carr’s index (%)* )* Hausner’s ratio* Angle of repose ( °)* 
F1 0.359±0.56 0.423±0.05 15.13±0.17 1.17±0.03 20.14±0.41 
F2 0.375±0.25 0.441±0.12 14.97±0.14 1.17±0.01 25.11±1.27 
F3 0.355±0.15 0.412±0.31 13.83±0.19 1.16±0.03 20.14±3.01 
F4 0.326±0.17 0.377±0.15 13.53±0.24 1.15±0.01 29.2±0.94 
F5 0.361±0.18 0.423±0.18 14.66±0.16 1.16±0.03 28.5±1.44 
F6 0.326±0.16 0.377±0.19 13.53±0.18 1.15±0.01 29.2±0.41 
F7 0.392±0.17 0.443±0.17 11.51±0.24 1.13±0.04 25.27±0.59 
F8 0.363±0.21 0.423±0.05 14.18±0.21 1.18±0.03 22.8±0.93 
F9 0.365±0.16 0.416±0.06 12.26± 0.04  1.14±0.02 25.23±0.32 
*mean±standard deviation (SD), n=3 
 
Table 3: Post-compression parameters 
Formulation Thickness (mm)* Hardness (kg/cm2 Friability (%)* )* Uniformity of weight (mg)* Assay (%)* 
F1 4.02 5.02 0.46 300.4 99.47 
F2 3.94 5.94 0.35 297.39 98.25 
F3 4.13 5.30 0.26 298.69 98.38 
F4 3.93 5.42 0.45 301.12 98.53 
F5 4.24 5.24 0.31 296.45 99.49 
F6 4.06 5.06 0.52 297.26 97.27 
F7 4.06 5.21 0.23 297.59 98.68 
F8 3.95 5.38 0.15 299.35 99.24 
F9 4.16 5.12 0.14 298.95 99.39 
*mean±standard deviation (SD), n=3 
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Table 4: In vitro buoyancy properties of losartan potassium 
Formulation Floating lag time (s)* Total floating time (h)* 
F1 63 >12 
F2 75 >12 
F3 95 >12 
F4 70 >12 
F5 85 >12 
F6 92 >12 
F7 87 >12 
F8 91 >12 
F9 98 >12 
*mean±standard deviation (SD), n=3 
 
Floating property  
The all GRDDS of losartan potassium floating lag time values vary in 
between 63 and 98 s and total floating time was found more than 12 h. 
FTIR studies 
In the current study, Fourier transforms infrared spectroscopy 
(FTIR) data of the best formulation were matched with the standard 
spectrum of pure drug losartan potassium over the range 400-4000 
cm-1 analyzed. The spectrum of pure losartan potassium shows 
prominent and strong absorption bands at wave numbers of 
1256.53 cm-1, 2870.26 cm-1, 3172.30 cm-1 and 762.24 cm-1
 
 
corresponding to cyclic amines, C-H stretches, O-H bending and 
Chlorine, respectively. The FTIR spectrum of the optimized 
formulation displayed the characteristic bands of both drug and 
excipient without any significant spectral shift. This suggested there 
was no potential chemical interaction between the components of 
the formulations. 
 
Fig. 1: FTIR spectrum of pure losartan potassium 
 
 
Fig. 2: FTIR spectrum of pure losartan potassium with excipients 
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Fig. 3: Percentage drug release of losartan potassium from formulation F1 to F9, all values were calculated mean±standard deviation; n=3 
 
Table 5: In vitro drug release kinetic studies of different formulations 
Formulation  Zero-order  First order  Higuchi Hixon Crowell Release 
exponent (n) Regression coefficient (R2) 
F1 0.975 0.629 0.926 0.802 0.868 
F2 0.962 0.71 0.958 0.854 0.669 
F3 0.93 0.613 0.863 0.754 0.760 
F4 0.949 0.976 0.978 0.969 0.987 
F5 0.981 0.985 0.986 0.989 0.759 
F6 0.99 0.988 0.988 0.993 0.780 
F7 0.989 0.715 0.959 0.872 0.913 
F8 0.976 0.842 0.965 0.939 0.515 
F9 0.951 0.668 0.894 0.813 0.496 
 
In vitro drug release profile 
In vitro dissolution studies were performed for all the batches of 
GRDDS of losartan potassium using USP XXIII dissolution test 
apparatus-II at 50 rpm, 900 ml of 0.1N HCl (pH 1.2) used as 
dissolution media. The in vitro drug release data was given in fig. 3. 
All the tablet formulations showed more than 8% drug release 
within 1 h, except F4, but formulation F8 showed maximum 23.17% 
drug release within 1 h. After the ideal study, drug release for 
formulations F1, and F4 (with HPMC k4m) were found to be 98.64%, 
after 10 h and 60.28% after 12 h, respectively. Formulations F2 and 
F5 have guar gum the drug releases 97.56%, after 10 h and 64.83% 
after 12 h, respectively, and same like Formulations F3 and F6 
having gum karaya the drug releases 98.65%, after 10 h and 65.24% 
after 12 h, respectively. As the drug release could only be observed 
up to 10 h in F1-F3 with the sustained release polymer 
concentration of 23%, a further high concentration of polymer 
29.6% was employed in F4-F6 to sustain the drug release up to 12 h, 
as the drug release was found to be a function of polymer 
concentration. As these results were far behind the satisfactory 
release rate, a combination of polymers in 1:1 ratio the 
concentration of 23% was employed to negotiate the slow release 
characteristics of F7 to F9 formulations, and the drug release was 
found to be optimum in F9 (97.77%) drug release having two 
natural gums, one is water-soluble (guar gum) and the other is 
water-insoluble (gum karaya) compared to F7 and F8. Hence, F9 was 
considered to be the optimized formulation. The drug release data 
were then fitted to mathematical models such as a zero-order, first-
order, Higuchi, Hixon-Crowell and Korsmeyer-Peppas model and the 
coefficients of regression values were compared [12]. It was 
observed that the formulations F1-F3 and F7-F9 followed zero-order 
release and formulation F4 followed Higuchi release kinetic. The 
formulations F5 and F6 follow Hixon-Crowell release kinetic. Among 
all nine formulations, F9 was selected as the best formulation. Data 
were then subjected to Korsmeyer-Peppas equation for 
determination of release mechanism and the release exponent ‘n’ 
varied from 0.496-0.987 that indicates F9 having Fickian diffusion 
and remaining F1 to F8 followed non-Fickian diffusion [13]. 
CONCLUSION 
This study discourses the formulation and evaluation of 
gastroretentive tablets of losartan potassium. The effervescent 
based floating drug delivery was a hopeful approach to achieve in 
vitro buoyancy. The addition of polymer HPMC k4m, natural 
polymers’ guar gum, gum karaya and gas generating agent sodium 
bicarbonate was important to achieve in vitro buoyancy. 
Formulation F9 showed a preferred drug release profile up to12 h 
following zero-order release kinetics and formulations F1 to F8 
followed non-Fickian diffusion except F9 was having Fickian 
diffusion. Thus, the conclusion of this research work clearly points 
out, a promising potential of this losartan potassium floating prolong 
release dosage form is as a substitute to the conventional dosage 
form for the management of hypertension. 
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